16th Clinical Biomarkers and CDx Summit Europe | Free* for Biopharma!

Memo

With IVDR performance study guidance now in force, German reimbursement reforms underway, and NHS England advancing liquid biopsy rollouts, Europe is entering a new era of precision medicine. As novel and digital diagnostics accelerate, the question is no longer whether they enable fit-for-purpose biomarker strategies, but how quickly clinical, regulatory, and commercial systems can keep pace. Amid this momentum, the 16th World Clinical Biomarkers and Companion Diagnostics Summit Europe returns as the region's longest-standing precision medicine forum, bringing together 300+ senior leaders across biopharma, diagnostics, regulation, reimbursement, and healthcare to define biomarker strategies and ensure day-one drug-diagnostic market readiness. Featuring brand-new case studies from 60+ expert speakers, this meeting is the definitive European platform for knowledge exchange and collaboration, removing barriers to faster, more equitable precision healthcare across oncology, neurological, autoimmune, and chronic diseases. URLs:Tickets: https://go.evvnt.com/3393347-2?pid=5569Brochure: https://go.evvnt.com/3393347-3?pid=5569 Date and Time: Monday, 30 March 2026 at 09:00 - Wednesday, 01 April 2026 at 17:00 Venue details: Novotel London West, 1 Shortlands Hammersmith International Center, London, England, W6 8DR, United Kingdom Category: Conferences | Science, Health and Medicine | Oncology Prices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): GBP 0.50,Drug Developer Pricing - 2 Day Pass (Conference Only): GBP 0.50,Solution Provider Pricing - 2 Day Pass (Conference Only): GBP 3299.00 Speakers: Charlotte Herd, Associate Director, International Marketing, Precision Medicine, Oncology, AbbVie, David Krige, Chief Development Officer, Accession Therapeutics, Monika Lamba, Global Translational Pathology Leader, ADC Therapeutics, Stewart McWilliams, Global Vice President, Quality and Regulatory Affairs, Almac Diagnostic Services, EK Kim, Head of Global Commercial Biomarkers and Diagnostics, Amgen, Aino Telaranta-Keerie, Senior Director, Global Precision Medicine Lead, Astellas Pharma, Sophie Wildsmith, Executive Director, Head of PMB Immuno-Oncology (IO) Franchise, AstraZeneca, Ruairidh Edwards, Translational Scientist, Avacta Therapeutics, Anna Ettorre, Director Translational Science, Bioassays and Biomarkers, AviadoBio, Kate Simon, Senior Director, Global Regulatory Strategy IVD, Bayer, Kathrin Schlüter, Medical Affairs Manager (Europe, Middle East, and Africa), BD Medical Essentials, Specimen Management, Dennis Merkle, CDx Commercialization Lead, Boehringer Ingelheim, Simon Vincent, Chief Scientific Officer, Breast Cancer Now, Jonathan Beer, Senior Director, Precision Medicine, Bristol Myers Squibb, Angela Douglas, President, British In Vitro Diagnostics Association, Dominic Smeithurst, Chief Medical Officer, Corbus Pharmaceuticals, Nicole Chaves Petronzi, Senior Director, Global Regulatory Affairs Diagnostics, Eli Lilly and Co, Matthew Brown, Chief Scientific Officer, Genomics England, Eleanor Barr, AI Product Manager, GlaxoSmithKline, Catherine Mela, Executive Director, Head Biomarker Operations, GlaxoSmithKline, Sarah Stanhope, Director Translational Medicine, Immunocore, Leonie De Visser, EMEA Disease Team Leader, Bladder Cancer, Johnson and Johnson, Innovative Medicine, Dany Bell, Strategic Adviser, Cancer Care, Macmillan Cancer Support, Lorna McInroy, Director, Clinical Biomarkers, Moderna, Kiri Granger, Co-Founder and Chief Scientific Officer, Monument Therapeutics, Radha Krishnan, Executive Director, Head of Clinical Pathology, MSD, Hilke Zander, Clinical Assessor, Paul-Ehrlich-Institut, National Competent Authority for Medicinal Products and CDx Devices, Jörg Engelbergs, Scientific-Regulatory Assessor Targeted and Personalized Biomedicines, Paul-Ehrlich-Institut, National Competent Authority for Medicinal Products and CDx Devices, Jason Simon, Precision Medicine Professional, Regeneron, Jai Pandey, Head, Global Device Regulatory for IVDs and Digital Health, Sanofi, Philip Beer, Chief Scientific Officer, Step Pharma, Franz Stark, Senior Manager, Quality Assurance IVDs, Takeda, Alastair Greystoke, Honorary Medical Oncologist and Professor of Oncology, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Rolf Thermann, Section Manager IVD and Companion Diagnostics Lead, TUV Rheinland, Paola Nasuti, Real-World Evidence Senior Strategy Lead, UCB, Neil Hawkins, Professor, Health Technology Assessment, University of Glasgow, Jose Munoz-Olaya, Chief Scientific Officer, Valink Therapeutics